| Crystal structure of human prorenin | |
Heteromer
| 29-406 | 100 | 1×NAG; |
|
| Crystal structure of the complex of human angiotensinogen and renin at 2.55 Angstrom | |
Heteromer
P01019; | 69-406 | 99.7 | 1×NAG; 1×NAG; 10×SO4; 1×GOL; |
|
| Crystal structure of human angiotensinogen complexed with renin | |
Heteromer
P01019; | 74-406 | 100.0 | |
|
| Crystal Structure of Human Renin Complexed with Inhibitor | | homo-6-mer | 69-406 | 100 | 3×7IG; |
|
| Crystal Structure of Human Renin Complexed with Inhibitor | | homo-6-mer | 69-406 | 100 | 6×LIX; 3×CIT; |
|
| Crystal Structure of Human Renin Complexed with Inhibitors | | homo-6-mer | 70-406 | 100 | 6×LIY; |
|
| Crystal Structure of Renin with Inhibitor 3 | | homo-6-mer | 70-406 | 100.0 | 6×C47; |
|
| Crystal structure at 2.6A of human prorenin | | homo-2-mer | 29-406 | 100.0 | 2×NAG; 10×SO4; |
|
| HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE … | | homo-2-mer | 70-406 | 100.0 | 2×NAG; 2×03D; |
|
| Optimization of Orally Bioavailable Alkyl Amine Renin Inhibitors | | homo-2-mer | 70-406 | 100 | 1×NAG; 4×22X; 1×NAG; |
|
| Design and optimization of new piperidines as renin inhibitors | | homo-2-mer | 70-406 | 100 | 1×NAG; 1×LPO; |
|
| Design and optimization of new piperidines as renin inhibitors | | homo-2-mer | 70-406 | 100 | 1×NAG; 1×LPQ; |
|
| Design and optimisation of new piperidines as renin inhibitors | | homo-2-mer | 70-406 | 100 | 1×NAG; 1×LPN; |
|
| CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | | homo-2-mer | 70-406 | 100.0 | 2×0IU; |
|
| CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS | | homo-2-mer | 70-406 | 100.0 | 2×0QB; |
|
| Crystal Structure of Renin with Inhibitor 8 | | homo-2-mer | 70-406 | 100.0 | 2×C39; |
|
| THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITIO… | | homo-2-mer | 71-406 | 100.0 | 2×NAG; 2×C60; |
|
| Human renin/PF02342674 complex | | homo-2-mer | 72-406 | 100 | 2×UA4; |
|
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | | monomer | 67-406 | 100.0 | 1×A7T; 2×NAG; |
|
| Structure-based design of 4-hydroxy-3,5-substituted piperidines as direct renin inhibitors | | monomer | 67-406 | 100.0 | 1×DMS; 1×NAG; 1×PO4; 1×2Y9; |
|
| Structure-Based Optimization of Potent 4- and 6-Azaindole-3-Carboxamides as Renin Inhibitors | | monomer | 67-406 | 100 | 1×NAG; 3×GOL; 2×S53; |
|
| Human renin in complex with compound2 | | monomer | 67-406 | 100.0 | 1×NAG; 1×UNL; |
|
| Crystal Structure of Renin with Inhibitor 10 (Aliskiren) | | monomer | 67-406 | 100.0 | 1×NAG; 1×C41; |
|
| Human renin in complex with compound1 | | monomer | 67-406 | 100 | 1×NAG; 1×UNL; |
|
| Crystal structure of renin in complex with NVP-AMQ838 (compound 5) | | monomer | 67-406 | 100.0 | 1×NAG; 1×0LR; |
|
| Crystal structure of renin in complex with NVP-BCH965 (compound 9) | | monomer | 67-406 | 100.0 | 1×NAG; 1×0MJ; 2×SO4; |
|
| Crystal structure of renin in complex with PKF909-724 (compound 3) | | monomer | 67-406 | 100.0 | 1×NAG; 2×0LU; 1×SO4; |
|
| Human renin in complex with compound 5 | | monomer | 67-406 | 100 | 1×NAG; 1×HHE; |
|
| Crystal structure of renin in complex with NVP-AYL747 (compound 5) | | monomer | 67-406 | 100.0 | 1×NAG; 1×0M3; 2×SO4; |
|
| Human renin in complex with compound3 | | monomer | 67-406 | 100 | 1×NAG; 1×UNL; |
|
| Human renin in complex with inhibitor 7 | | monomer | 67-406 | 100.0 | 1×NAG; 1×VYE; |
|
| Crystal structure of renin in complex with NVP-BBV031 (compound 6) | | monomer | 67-406 | 100.0 | 1×NAG; 1×0ME; 1×SO4; |
|
| Human renin in complex with compound 18 | | monomer | 67-406 | 100 | 1×NAG; 1×R32; |
|
| Human renin in complex with inhibitor 9 | | monomer | 67-406 | 100.0 | 1×NAG; 1×VYF; |
|
| Human renin in complex with inhibitor 6 | | monomer | 67-406 | 100.0 | 1×NAG; 1×VYD; |
|
| Human renin in complex with compound 8 | | monomer | 67-406 | 100 | 1×NAG; 1×R31; |
|
| Renin in complex with (S)-1-(3-fluoro-5-(((S)-1-phenylethyl)carbamoyl)benzyl)-4-isopropyl-4-methyl-… | | monomer | 68-406 | 100 | 1×NAG; 1×43T; |
|
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | | monomer | 68-406 | 100.0 | 1×NAG; 1×74U; 1×PEG; |
|
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | | monomer | 68-406 | 100.0 | 1×NAG; 1×74V; 1×PGE; 2×DMS; |
|
| Renin in complex with (S)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimid… | | monomer | 68-406 | 100 | 1×NAG; 1×70X; |
|
| Renin in complex with (4S)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4-phenylpyrrolidin-1-yl)benzyl)te… | | monomer | 68-406 | 100 | 1×NAG; 1×70Y; |
|
| RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]ami… | | monomer | 68-406 | 100.0 | 1×NAG; 1×3ZK; 1×SO4; |
|
| Crystal structure of renin in complex with NVP-AYZ832 (compound 6a) | | monomer | 68-406 | 100.0 | 1×NAG; 2×0LS; 1×SO4; |
|
| RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-methoxy-3-(3-methoxypropoxy)benzoyl](propan-2-yl)amino}methy… | | monomer | 68-406 | 100.0 | 1×NAG; 1×3ZN; 1×SO4; |
|
| Novel Approach of Fragment-Based Lead Discovery applied to Renin Inhibitors | | monomer | 68-406 | 100.0 | 1×NAG; 1×PG6; 2×DMS; |
|
| RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(benzylsulfonyl)amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3… | | monomer | 68-406 | 100.0 | 1×NAG; 1×3ZJ; 1×SO4; |
|
| Crystal structure of renin in complex with NVP-BGQ311 (compound 12) | | monomer | 68-406 | 100.0 | 1×NAG; 1×0N0; 1×SO4; |
|
| Crystal structure of renin in complex with NVP-BCA079 (compound 12a) | | monomer | 68-406 | 100.0 | 1×NAG; 1×0LT; 1×SO4; |
|
| Crystal structure of renin in complex with GP055321 (compound 4) | | monomer | 69-406 | 100.0 | 1×NAG; 1×0M2; |
|
| Crystal structure of renin in complex with compound4 | | monomer | 69-406 | 100.0 | 1×NAG; 1×2XF; 1×DMS; 1×SO4; |
|
| New Classes of Potent and Bioavailable Human Renin Inhibitors | | monomer | 70-406 | 100.0 | 1×BFX; 1×FMT; 1×NAG; |
|
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | | monomer | 70-406 | 100.0 | 1×DMS; 1×NAG; 1×A6T; |
|
| Crystal structure of human renin complexed with a novel inhibitor | | monomer | 70-406 | 100 | 1×NAG; 1×72X; 4×GOL; 1×CL; |
|
| Design and Preparation of Potent, Non-Peptidic, Bioavailable Renin Inhibitors | | monomer | 70-406 | 100.0 | 1×A5T; 1×DMS; 1×NAG; |
|
| Potent macrocyclic renin inhibitors | | monomer | 70-406 | 100.0 | 3×ACT; 2×NA; 1×3OX; |
|
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | | monomer | 70-406 | 100.0 | 1×NAG; 1×6VU; 1×PGE; 3×PEG; 8×DMS; |
|
| Clinically Useful Alkyl Amine Renin Inhibitors | | monomer | 70-406 | 100 | 1×NAG; 4×CL; 1×RX6; |
|
| Clinically Useful Alkyl Amine Renin Inhibitors | | monomer | 70-406 | 100 | 1×NAG; 4×CL; 1×RX5; |
|
| Human renin in complex with remikiren | | monomer | 70-406 | 100.0 | 1×REM; 1×DMS; |
|
| Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | | monomer | 70-406 | 100.0 | 1×NAG; 1×7EK; 1×PGE; 1×PEG; 3×DMS; |
|
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | | monomer | 70-406 | 100.0 | 1×NAG; 1×74Z; 6×DMS; 1×PEG; 1×1PE; |
|
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | | monomer | 70-406 | 100.0 | 1×NAG; 1×6VS; 8×DMS; 2×PEG; |
|
| STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RE… | | monomer | 70-406 | 100.0 | 1×NAG; |
|
| Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | | monomer | 70-406 | 100 | 1×NAG; 1×SSR; |
|
| Alkyl Amine Renin Inhibitors: Filling S1 from S3 | | monomer | 70-406 | 100 | 1×NAG; 1×RX0; 2×GOL; |
|
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | | monomer | 70-406 | 100 | 1×NAG; 2×90D; |
|
| Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active … | | monomer | 70-406 | 100.0 | 1×NAG; 1×7EJ; 3×DMS; |
|
| Crystal Structure Analysis of Renin-indole-piperazine inhibitor complexes | | monomer | 70-406 | 100 | 1×NAG; 1×S51; |
|
| Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibi… | | monomer | 70-406 | 100.0 | 1×NAG; 1×74Y; 3×PEG; |
|
| Crystal Structure Analysis of Renin-indole-piperazin inhibitor complexes | | monomer | 70-406 | 100 | 1×NAG; 1×S52; |
|
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | | monomer | 70-406 | 100.0 | 1×NAG; 1×9G7; 1×SO4; |
|
| Crystal Structure of Renin with Inhibitor 9 | | monomer | 70-406 | 100.0 | 1×C61; |
|
| Crystal Structure of Renin with Inhibitor 6 | | monomer | 70-406 | 100.0 | 1×C80; |
|
| Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol | | monomer | 70-406 | 100.0 | 1×NAG; 1×SO4; 2×9JD; |
|
| Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor | | monomer | 71-406 | 100.0 | 1×NAG; 1×6VR; |
|
| Crystal Structure of Renin with Inhibitor 7 | | monomer | 71-406 | 100.0 | 1×C40; |
|
| X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN … | | monomer | 72-406 | 100.0 | |
|
| crystal structure of renin-pf00257567 complex | | monomer | 73-406 | 100.0 | 1×RPF; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100.0 | 1×7IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100.0 | |
|
| crystal structure of Renin-PF00074777 complex | | monomer | 74-406 | 100.0 | |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C ring | | monomer | 74-406 | 100.0 | |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100.0 | 1×L1B; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | | monomer | 74-406 | 100 | 1×L1A; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | | monomer | 74-406 | 100 | 1×NAG; 1×3IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100 | 1×NAG; 1×6IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100 | 1×NAG; 1×5IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the C Ring | | monomer | 74-406 | 100 | 1×NAG; 1×4IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100 | 1×NAG; 1×2IG; |
|
| Ketopiperazine-based renin inhibitors: Optimization of the "C" ring | | monomer | 74-406 | 100 | 1×NAG; 1×1IG; |
|
| Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring | | monomer | 74-406 | 100.0 | 1×4LG; |
|